Barclays’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-79,034
| Closed | -$8.06M | – | 4766 |
|
|
2023
Q2 | $8.06M | Buy |
79,034
+62,278
| +372% | +$5.89M | 0.01% | 1071 |
|
|
2023
Q1 | $1.52M | Buy |
16,756
+886
| +6% | +$52K | ﹤0.01% | 2412 |
|
|
2022
Q4 | $603K | Buy |
15,870
+2,008
| +14% | +$69.1K | ﹤0.01% | 3190 |
|
|
2022
Q3 | $348K | Sell |
13,862
-1,769
| -11% | -$49K | ﹤0.01% | 2888 |
|
|
2022
Q2 | $475K | Sell |
15,631
-13,279
| -46% | -$396K | ﹤0.01% | 2900 |
|
|
2022
Q1 | $948K | Sell |
28,910
-31,981
| -53% | -$949K | ﹤0.01% | 2454 |
|
|
2021
Q4 | $1.61M | Buy |
60,891
+35,192
| +137% | +$2.72M | ﹤0.01% | 2511 |
|
|
2021
Q3 | $2.58M | Buy |
25,699
+20,801
| +425% | +$2.44M | ﹤0.01% | 2128 |
|
|
2021
Q2 | $693K | Sell |
4,898
-2,959
| -38% | -$334K | ﹤0.01% | 2887 |
|
|
2021
Q1 | $784K | Buy |
7,857
+5,816
| +285% | +$678K | ﹤0.01% | 2919 |
|
|
2020
Q4 | $252K | Sell |
2,041
-302
| -13% | -$39.7K | ﹤0.01% | 3635 |
|
|
2020
Q3 | $229K | Sell |
2,343
-17,586
| -88% | -$2.2M | ﹤0.01% | 3761 |
|
|
2020
Q2 | $3.11M | Sell |
19,929
-11,682
| -37% | -$1.78M | ﹤0.01% | 1745 |
|
|
2020
Q1 | $4.56M | Sell |
31,611
-2,794
| -8% | -$539K | ﹤0.01% | 1540 |
|
|
2019
Q4 | $7.03M | Buy |
34,405
+24,495
| +247% | +$4.47M | ﹤0.01% | 1683 |
|
|
2019
Q3 | $796K | Sell |
9,910
-3,062
| -24% | -$260K | ﹤0.01% | 3868 |
|
|
2019
Q2 | $1.22M | Sell |
12,972
-785
| -6% | -$67.8K | ﹤0.01% | 3474 |
|
|
2019
Q1 | $1.18M | Buy |
13,757
+4,173
| +44% | +$346K | ﹤0.01% | 3228 |
|
|
2018
Q4 | $537K | Buy |
9,584
+2,511
| +36% | +$153K | ﹤0.01% | 3740 |
|
|
2018
Q3 | $578K | Buy |
7,073
+5,905
| +506% | +$416K | ﹤0.01% | 4150 |
|
|
2018
Q2 | $41K | Sell |
1,168
-3,048
| -72% | -$92.8K | ﹤0.01% | 5764 |
|
|
2018
Q1 | $87K | Buy |
4,216
+720
| +21% | +$18.5K | ﹤0.01% | 5481 |
|
|
2017
Q4 | $99K | Sell |
3,496
-432
| -11% | -$12.1K | ﹤0.01% | 5252 |
|
|
2017
Q3 | $122K | Buy |
3,928
+3,734
| +1,925% | +$112K | ﹤0.01% | 4791 |
|
|
2017
Q2 | $6K | Buy |
194
+16
| +9% | +$393 | ﹤0.01% | 6203 |
|
|
2017
Q1 | $4K | Sell |
178
-803
| -82% | -$19.8K | ﹤0.01% | 6350 |
|
|
2016
Q4 | $21K | Buy |
981
+944
| +2,551% | +$23.9K | ﹤0.01% | 5607 |
|
|
2016
Q3 | $1K | Sell |
37
-6,047
| -99% | -$120K | ﹤0.01% | 6480 |
|
|
2016
Q2 | $120K | Buy |
+6,084
| New | +$118K | ﹤0.01% | 4278 |
|
Other funds holding RETA
Barclays's RETA Position: Q3 2023 in Review
Barclays sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 79,034 shares — an estimated $8.06M sold.
Barclays first reported a position in RETA in Q2 2016 and held it in 29 quarters. The position peaked at $8.06M in Q2 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.
- Barclays reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
- Barclays sold 79,034 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $8.06M.
- Barclays first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2016 and held it in 29 quarters.
- Barclays's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $8.06M in Q2 2023.
- 2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.
Based on Barclays's 13F filing for Q3 2023, filed 7 Nov 2023.